The short version of peptide analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase is an enzyme that in humans is encoded by the MGAT1 gene. There are over 100 different glycosyltransferases involved in the synthesis of protein-bound and lipid-bound oligosaccharides. UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I is a medial-Golgi enzyme essential for the synthesis of hybrid and complex N-glycans. The protein, encoded by a single exon, shows typical features of a type II transmembrane protein. The protein is believed to be essential for normal embryogenesis.
The Tempest (2001) - Boatswain I Dreamt of Bombay (2002) - Bobby Girlfriends (2002) - Guy Hulk (2003) - Soldier Ball & Chain (2004) - Monty War of the Worlds (2005) - Boston Soldier Over There (2005) - Sergeant First Class Neeson Cold Case (2006) - Wes Floyd Veronica Mars (2007) I Gotta Be Better Than Keanu (2007) - Slimy Agent Scrubs (2001–2009) - Dr. Doug Murphy The Beast (2009) - Todd Jaracki
=== Life support systems === With nuclear power or air-independent propulsion, submarines can remain submerged for months at a time. Conventional diesel submarines must periodically resurface or run on snorkel to recharge their batteries. Most modern military submarines generate breathing oxygen by electrolysis of fresh water (using a device called an "Electrolytic Oxygen Generator"). Emergency oxygen can be produced by burning sodium chlorate candles. Atmosphere control equipment includes a Carbon dioxide scrubber, which uses a spray of monoethanolamine (MEA) absorbent to remove the gas from the air, after which the MEA is heated in a boiler to release the CO2 which is then pumped overboard. Emergency scrubbing can also be done with lithium hydroxide, which is consumable. A machine that uses a catalyst to convert carbon monoxide into carbon dioxide (removed by the CO2 scrubber) and bonds hydrogen produced from the ship's storage battery with oxygen in the atmosphere to produce water, is also used. An atmosphere monitoring system samples the air from different areas of the ship for nitrogen, oxygen, hydrogen, R-12 and R-114 refrigerants, carbon dioxide, carbon monoxide, and other gases. Poisonous gases are removed, and oxygen is replenished by use of an oxygen bank located in a main ballast tank. Some heavier submarines have two oxygen bleed stations (forward and aft). The oxygen in the air is sometimes kept a few percent less than atmospheric concentration to reduce fire risk. Fresh water is produced by either an evaporator or a reverse osmosis unit.
== Elements by number of primordial isotopes == An even number of protons or neutrons is more stable (higher binding energy) because of pairing effects, so even–even nuclides are much more stable than odd–odd. One effect is that there are few stable odd–odd nuclides: in fact only five are stable, with another four having half-lives longer than a billion years. Another effect is to prevent beta decay of many even–even nuclides into another even–even nuclide of the same mass number but lower energy, because decay proceeding one step at a time would have to pass through an odd–odd nuclide of higher energy. (Double beta decay directly from even–even to even–even, skipping over an odd-odd nuclide, is possible, but is so strongly hindered that known cases have half-lives greater than 108 times the age of the universe.) This makes for a larger number of stable even–even nuclides, up to three for some mass numbers, up to seven for some atomic (proton) numbers, with at least four for all stable even-Z elements beyond argon. Since nuclei with odd numbers of protons are relatively less stable, odd-numbered elements tend to have fewer stable isotopes. Of the 26 monoisotopic elements (those with exactly one stable isotope), all but one have an odd atomic number—the single exception being beryllium. In addition, no odd-numbered element has more than two stable isotopes, while every even-numbered element heavier than carbon with stable isotopes has at least three. Only a single odd-numbered element, potassium, has three primordial isotopes and none more than that.
Sources: en.wikipedia.org
Sheikha Fatima bint Hazza bin Zayed Al Nahyan. Sheikha Salama bint Hazza bin Zayed Al Nahyan. Sheikh Zayed bin Hazza bin Zayed Al Nahyan (born 1995). He has one son. Sheikh Hazza bin Zayed Al Nahyan (born 2026). Sheikha Meera bint Hazza bin Zayed Al Nahyan. She married Sheikh Zayed bin Mansour bin Zayed Al Nahyan on May 5, 2022. Sheikh Mohammed bin Hazza bin Zayed Al Nahyan (born 2002).
Integration of graphene (thickness of 0.34 nm) layers as nanoelectrodes into a nanopore can potentially solve a bottleneck for nanopore-based single-molecule DNA sequencing. On November 20, 2013, the Bill & Melinda Gates Foundation awarded $100,000 'to develop new elastic composite materials for condoms containing nanomaterials like graphene'. In 2014, graphene-based, transparent (across infrared to ultraviolet frequencies), flexible, implantable medical sensor microarrays were announced that allow the viewing of brain tissue hidden by implants. Optical transparency was greater than 90%. Applications demonstrated include optogenetic activation of focal cortical areas, in vivo imaging of cortical vasculature via fluorescence microscopy and 3D optical coherence tomography.
In the summer of 1969, weary from these activities, Adorno returned once again to Zermatt, Switzerland, at the foot of Matterhorn to restore his strength. On 6 August, during a vacation in Visp, he died of a heart attack.
Sources: en.wikipedia.org
A connective tissue nevus is a skin lesion which may be present at birth or appear within the first few years of life. It is elevated, soft to firm in consistency, varying in size from 0.5 to several centimeters in diameter, and may manifest as grouped, linear, or irregularly-distributed lesions.
On 26 February, Agüero's sisters Natalia Agüero and Celeste Severín gave an impact testimony, saying that they do not believe their sister is a murderer, and asked for her acquittal. Natalia Agüero highlighted Brenda's upbringing with their parents and the impact that their divorce had on her. She also told of their time in Buenos Aires and then back in Río Ceballos and how Brenda allegedly dedicated herself to her job. Celeste Severín said that her sister is a perejil (lit. parsley) which is Argentinian slang for "fool", and was allowed to hug Brenda before exiting the courtroom. On 10 March, the Homicides Division of Córdoba Police presented another report accusing Agüero of being the only person with an "active participation" in every case. The investigators highlighted that in the case of 1 May 2022 (baby G.H.), Agüero predicted that the baby would decompensate, even when the baby was healthy and without any complications. On 11 March, the prosecution presented a series of photographs taken from Agüero's cell phone. The court chose three of those for evaluation by psychologists and psychiatrists: one photo of babies in incubators, another picture of a vial of vitamin K, and a third picture that showed the hand of a baby with three red spots on it. Said evaluators found that the pictures relate closely to Agüero's psychopathic personality, especially under the lack of empathy shown to the families of the victims. On 15 April, Agüero began her final statement before the court, where she denied committing the murders.
The Army Reserve is the volunteer reserve force of the British Army. It is separate from the Regular Reserve whose members are ex-regular personnel who retain a statutory liability for service. Descended from the Territorial Force (1908 to 1921), the Army Reserve was known as the Territorial Army (TA) from 1921 to 1967 and again from 1979 to 2014, and the Territorial and Army Volunteer Reserve (TAVR) from 1967 to 1979. The force was created in 1908 by the Secretary of State for War, Richard Haldane, when the Territorial and Reserve Forces Act 1907 combined the previously civilian-administered Volunteer Force, with the mounted Yeomanry (at the same time the Militia was renamed the Special Reserve). Haldane planned a volunteer "Territorial Force", to provide a second line for the six divisions of the Expeditionary Force which he was establishing as the centerpiece of the Regular Army. The Territorial Force was to be composed of fourteen divisions of infantry and fourteen brigades of cavalry, together with all the supporting arms and services needed for overseas war, including artillery, engineers, commissariat and medical support. The new Special Reserve was to take over the depots of the militia, as an expanded reserve for the Regular Army. Under multiple political pressures, Haldane made a last-minute alteration to his Territorial and Reserve Forces Act; the public purpose of the Territorial Force was changed to home defence, although its planned structure was left intact.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.